Laurent Chardonnet - Dec 8, 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role: Chief Financial Officer
Signature: /s/ Krishna Vaddi, Attorney-in-Fact
Stock symbol: PRLD
Transactions as of: Dec 8, 2022
Transactions value $: $47,600
Form type: 4
Date filed: 12/12/2022, 08:13 AM
Previous filing: Jun 1, 2022
Next filing: Dec 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRLD	Common Stock	Purchase	$47.6K	+10K	+38.65%	$4.76	35.9K	Dec 8, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F2	The reported total includes 1,373 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

The reported total includes 1,373 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).